73 related articles for article (PubMed ID: 9108994)
1. Therapeutic intervention in glomerulonephritis by oligonucleotides.
Kashihara N; Maeshima Y; Makino H
Exp Nephrol; 1997; 5(2):126-31. PubMed ID: 9108994
[No Abstract] [Full Text] [Related]
2. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
[TBL] [Abstract][Full Text] [Related]
3. Treatment of chronic myelogenous leukemia (CML) with c-myb antisense oligodeoxynucleotides.
Gewirtz AM
Bone Marrow Transplant; 1994; 14 Suppl 3():S57-61. PubMed ID: 7697011
[No Abstract] [Full Text] [Related]
4. Posttranscriptional regulation of the c-myb proto-oncogene in estrogen receptor-positive breast cancer cells.
Gudas JM; Klein RC; Oka M; Cowan KH
Clin Cancer Res; 1995 Feb; 1(2):235-43. PubMed ID: 9815978
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic effect of sodium nitroprusside on cancer cells: involvement of apoptosis and suppression of c-myc and c-myb proto-oncogene expression.
Sumitani K; Kamijo R; Nagumo M
Anticancer Res; 1997; 17(2A):865-71. PubMed ID: 9137419
[TBL] [Abstract][Full Text] [Related]
6. Myb targeted therapeutics for the treatment of human malignancies.
Gewirtz AM
Oncogene; 1999 May; 18(19):3056-62. PubMed ID: 10378701
[TBL] [Abstract][Full Text] [Related]
7. Oligonucleotide therapeutics for human leukaemia.
Gewirtz AM
Ciba Found Symp; 1997; 209():169-91; discussion 191-4. PubMed ID: 9383576
[TBL] [Abstract][Full Text] [Related]
8. c-Myb function in fibroblasts.
Bein K; Husain M; Ware JA; Mucenski ML; Rosenberg RD; Simons M
J Cell Physiol; 1997 Dec; 173(3):319-26. PubMed ID: 9369944
[TBL] [Abstract][Full Text] [Related]
9. The expression of C-myb in human metastatic melanoma cell lines and specimens.
Walker MJ; Silliman E; Dayton MA; Lang JC
Anticancer Res; 1998; 18(2A):1129-35. PubMed ID: 9615777
[TBL] [Abstract][Full Text] [Related]
10. Linking Myb to the cell cycle: cyclin-dependent phosphorylation and regulation of A-Myb activity.
Ziebold U; Klempnauer KH
Oncogene; 1997 Aug; 15(9):1011-9. PubMed ID: 9285555
[TBL] [Abstract][Full Text] [Related]
11. Exploring RNA interference as a therapeutic strategy for renal disease.
Takabatake Y; Isaka Y; Mizui M; Kawachi H; Shimizu F; Ito T; Hori M; Imai E
Gene Ther; 2005 Jun; 12(12):965-73. PubMed ID: 15729369
[TBL] [Abstract][Full Text] [Related]
12. Redundant functions of B-Myb and c-Myb in differentiating myeloid cells.
Golay J; Broccoli V; Borleri GM; Erba E; Faretta M; Basilico L; Ying GG; Piccinini G; Shapiro LH; Lovrić J; Nawrath M; Mölling K; Rambaldi A; Introna M
Cell Growth Differ; 1997 Dec; 8(12):1305-16. PubMed ID: 9419419
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of a c-Myb/estrogen receptor fusion protein in transformed primary cells leads to granulocyte/macrophage differentiation and down regulation of c-kit but not c-myc or cdc2.
Hogg A; Schirm S; Nakagoshi H; Bartley P; Ishii S; Bishop JM; Gonda TJ
Oncogene; 1997 Dec; 15(24):2885-98. PubMed ID: 9416832
[TBL] [Abstract][Full Text] [Related]
14. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
[TBL] [Abstract][Full Text] [Related]
15. Cell-cycle progression is not essential for c-Myc to block differentiation.
Ryan KM; Birnie GD
Oncogene; 1997 Jun; 14(23):2835-43. PubMed ID: 9190900
[TBL] [Abstract][Full Text] [Related]
16. Antisense oligonucleotides directed at cell cycle regulatory genes as strategy for restenosis therapy.
Morishita R; Gibbons GH; Ellison KE; Nakajima M; von der Leyen H; Zhang L; Kaneda Y; Ogihara T; Dzau VJ
Trans Assoc Am Physicians; 1993; 106():54-61. PubMed ID: 8036745
[No Abstract] [Full Text] [Related]
17. The c-myb proto-oncogene: a novel target for human gene therapy.
Gewirtz AM
Cancer Treat Res; 1996; 84():93-112. PubMed ID: 8724627
[No Abstract] [Full Text] [Related]
18. [Antisense oligonucleotides inhibit c-myc and PCNA expression in the vascular smooth muscle cells].
Bian J; Zhang B; Chen S
Zhonghua Yi Xue Za Zhi; 1999 Jan; 79(1):10-4. PubMed ID: 11600998
[TBL] [Abstract][Full Text] [Related]
19. The proto-oncogene c-myb mediates an intracellular calcium rise during the late G1 phase of the cell cycle.
Simons M; Morgan KG; Parker C; Collins E; Rosenberg RD
J Biol Chem; 1993 Jan; 268(1):627-32. PubMed ID: 8416967
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of antisense phosphorothioate c-myc oligodeoxynucleotides: a question of mechanism.
Stein CA
J Natl Cancer Inst; 1996 Apr; 88(7):391-3. PubMed ID: 8618230
[No Abstract] [Full Text] [Related]
[Next] [New Search]
